Functional classes III and IV of congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD), stages 4 and 5 of chronic kidney disease (GFR <30 mL/min), diabetic ketoacidosis, known history of HIV/AIDS infection or chronic or acute HBV or HCV infection, uncontrolled bacterial or fungal co-infections (defined by hemodynamic instability, prior 48h of antimicrobial covering, or at the discretion of the study's medical coordinator), active tuberculosis (TB) infection, history of malignancy in the last year, current users (or in the last 15 days) of immunosuppressants (synthetic or biologic) or corticosteroids (in doses equivalent to or greater than 10mg of prednisone per day), neutrophils count <1000/mm3, pregnancy or breastfeeding (pregnancy test will be performed during the screening period, before the inclusion, in all women of childbearing potential).

Functional classes III and IV of congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD), stages 4 and 5 of chronic kidney disease (GFR <30 mL/min), diabetic ketoacidosis, known history of HIV/AIDS infection or chronic or acute HBV or HCV infection, uncontrolled bacterial or fungal co-infections (defined by hemodynamic instability, prior 48h of antimicrobial covering, or at the discretion of the study's medical coordinator), active tuberculosis (TB) infection, history of malignancy in the last year, current users (or in the last 15 days) of immunosuppressants (synthetic or biologic) or corticosteroids (in doses equivalent to or greater than 10mg of prednisone per day), neutrophils count <1000/mm3, pregnancy or breastfeeding (pregnancy test will be performed during the screening period, before the inclusion, in all women of childbearing potential).